# About Doctor Wolverine — The Editorial Position > Doctor Wolverine is an independent editorial reading hall for the BPC-157 + TB-500 research literature. Not a clinic. Not a vendor. Not a treatment provider. Editorial standards and disclaimer. ## I. What Doctor Wolverine is Doctor Wolverine is an independent editorial project that publishes summaries of the peer-reviewed research literature on the BPC-157 and TB-500 peptide pairing — a combination sometimes referred to by the research-community vernacular nickname "the Wolverine blend." The publication treats the existing literature as a body of text and reads it carefully: which studies were done, in which species, at which doses, by which route, with what endpoints, and what the gaps are. The site is set as a kind of typographic broadside on a cream page. The "Doctor" modifier in the brand name is editorial — it describes the publication's position as a doctor of letters relative to a body of research, in the older sense of the word. It does not describe a clinical service, a treatment provider, or a medical practice. ## II. What Doctor Wolverine is not Doctor Wolverine is not a clinic. It does not employ clinicians and does not provide medical advice. It does not manufacture, sell, or distribute any product. It is not affiliated with any vendor, supplier, compounding pharmacy, telehealth provider, or laboratory. It does not offer consultations. It does not write prescriptions. It does not refer readers to providers. The work on this site is editorial commentary on publicly available science. Doctor Wolverine is not affiliated with Marvel Entertainment, Marvel Comics, The Walt Disney Company, or any holder of related trademarks. The word "Wolverine" in the publication's name and in the research-community phrase "the Wolverine blend" is a descriptive nickname for a rapid-healing phenotype reported in rodent models. It is not a reference to any character, costume, story, or property. The publication carries no imagery, terminology, or visual vocabulary borrowed from any such property. ## III. Editorial standards Every quantitative claim on the site is sourced to a peer-reviewed publication, a regulatory document, or a clinical-trial registry entry. The reference list is numbered and linked. Sources are weighted by where the data come from: human studies are distinguished from animal studies, full-length thymosin beta-4 is distinguished from the seven-amino-acid TB-500 fragment, controlled trials are distinguished from case series, and case series from a single investigator group are flagged as such [6][25]. The site does not recommend doses. It does not propose treatment protocols. It does not endorse vendors. Where the literature is silent or thin — most notably on the BPC-157 + TB-500 combination, which has no published peer-reviewed combination study — the silence is named [6][7][25]. Where vendor literature attributes data from full-length thymosin beta-4 to the seven-amino-acid TB-500 fragment, the attribution is corrected [22]. Where a regulatory record exists, it is reported. Both compounds were placed on the FDA Category 2 list of 503A bulk drug substances in September 2023. BPC-157 is on the WADA Prohibited List under category S0. TB-500 / thymosin beta-4 is on the WADA Prohibited List under category S2. ## IV. Sourcing methodology The literature reviewed for this publication includes papers indexed on PubMed and PMC, registered trials on ClinicalTrials.gov, regulatory notices from the FDA and EMA, the WADA Prohibited List, and clinical-trial publications in Nature, Cornea, Annals of the New York Academy of Sciences, Journal of Cellular and Molecular Medicine, Journal of Orthopaedic Research, Frontiers in Pharmacology, HSS Journal, Current Reviews in Musculoskeletal Medicine, Pharmaceuticals, Pharmaceutics, Medicina, Investigative Ophthalmology & Visual Science, Glia, Vitamins and Hormones, Molecules, and Expert Opinion on Biological Therapy. Where a 2024 or 2025 review exists, the review's catalogue is treated as the most current map of the underlying primary literature. Where a primary paper is older than its current review, the primary paper is read directly and cited in addition to the review. ## V. Disclaimer and the reader's contract The disclaimer that appears in the footer of every page is the contract between the publication and the reader: for research purposes only; not for human consumption; the site does not sell any product and is not affiliated with any vendor. Nothing on this site is medical advice. Readers who are considering any decision about peptide research should consult a qualified clinician and rely on primary peer-reviewed sources rather than on this publication or any other secondary source. ## References [6] McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157. Curr Rev Musculoskelet Med. 2025;18(12):611-619. [7] Vasireddi N, et al. Emerging Use of BPC-157. HSS Journal. 2025. [22] Safer D, Elzinga M, Nachmias VT. Thymosin β4 — actin sequestration. J Biol Chem. 1991;266(7):4029-4032. [25] McGuire FP, et al. Regeneration or Risk? — combination commentary. Curr Rev Musculoskelet Med. 2025;18(12):611-619. --- For research purposes only. Not for human consumption. This site does not sell any product and is not affiliated with any vendor.